샘플 요청 목록

 카트 문의
시장보고서
상품코드
2154160

패혈증 진단약 시장

Sepsis Diagnostics
발행일: | 리서치사: 구분자 Market Glass, Inc. | 페이지 정보: 영문 580 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기는 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 5,850 금액 안내 화살표 ￦ 7,891,000
PDF & Excel (Team License: Up to 10 users) help
PDF & Excel 보고서를 동일 기업 내 최대 10명까지 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기가 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 이용자 1명당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 11,115 금액 안내 화살표 ￦ 14,993,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel 보고서를 동일 기업 및 100% 자회사의 모든 분이 이용하실 수 있는 라이선스입니다. 인쇄는 1인당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 17,550 금액 안내 화살표 ￦ 23,673,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 패혈증 진단약 시장은 2032년까지 19억 달러에 달할 전망

2025년에 12억 달러로 추정되는 세계의 패혈증 진단 시장은 2032년까지 19억 달러에 달할 것으로 예상되고 있으며, 2025-2032년의 분석 기간에 CAGR 7.2%로 성장할 것으로 전망되고 있습니다. 이 리포트에서 분석 대상이 되고 있는 부문의 하나인 진단 기기는 CAGR 9.1%를 기록하며, 분석 기간의 종료시점까지 7억 6,220만 달러에 달할 것으로 예상되고 있습니다. 혈액 배양 배지 부문의 성장률은 분석 기간 중 CAGR 5.3%로 추정되고 있습니다.

미국 시장은 3억 1,900만 달러로 추계되는 한편, 중국은 CAGR 11.4%로 성장할 것으로 예측됩니다.

미국의 패혈증 진단 시장은 2025년에 3억 1,900만 달러로 추계되고 있습니다. 세계 2위의 경제 규모를 자랑하는 중국은 2025-2032년의 분석 기간에 CAGR 11.4%로 추이하며, 2032년까지 시장 규모가 4억 3,960만 달러에 달할 것으로 예측됩니다. 기타 주목할 만한 지역 시장으로는 일본과 캐나다를 들 수 있으며, 분석 기간 중 각각 CAGR 3.4% 및 7.0%로 성장할 것으로 예측됩니다. 유럽내에서는 독일이 CAGR 약 4.7%로 성장할 것으로 예측됩니다.

세계의 패혈증 진단 시장 - 주요 동향과 촉진요인 정리

왜 첨단 패혈증 진단법에 대한 수요가 급속히 증가하고 있는가?

감염에 대한 신체의 과잉 반응으로 인해 발생하는 생명을 위협하는 상태인 패혈증은 여전히 전 세계에서 주요 사망 원인 중 하나입니다. 환자의 예후를 개선하고 의료비를 절감하기 위해 필수적인 조기 발견과 적시 개입이 요구됨에 따라 첨단 패혈증 진단법에 대한 수요가 급속히 증가하고 있습니다. 기존의 진단법에서는 시간 지연, 정확도 문제, 그리고 초기 단계에서 패혈증을 식별하기 어렵다는 등의 과제에 종종 직면하고 있습니다. 이에 대응하여 병원 및 임상 검사실에서는 패혈증을 정확하고 신속하게 진단할 수 있도록 분자 진단, 신속 항원 검사, 바이오마커 기반 검사 등 혁신적인 진단 솔루션의 도입이 점점 더 확대되고 있습니다. 특히 중환자실(ICU) 및 응급실에서의 높은 패혈증 유병률은 전 세계에서 이러한 첨단 진단 툴의 도입을 더욱 촉진하고 있습니다.

기술의 발전은 패혈증 진단에 어떤 영향을 미치고 있는가?

기술의 발전은 패혈증 진단 분야를 대폭 강화하여 정확성, 속도, 신뢰성을 향상시키고 있습니다. 중합효소 연쇄 반응(PCR) 및 차세대 염기서열 분석(NGS)을 포함한 분자 진단의 혁신으로 인해 병원체와 그 항생제 내성 프로파일을 신속하게 규명할 수 있게 되어 표적 치료의 시행이 촉진되고 있습니다. 또한 자동화 플랫폼과 현장 진단(POC) 기기의 개발로 인해 진단 기능이 환자 침대 바로 옆에서 이루어지게 되어, 결과 도출 시간이 단축되고 임상적 의사결정이 개선되고 있습니다. 또한 AI 및 기계학습 알고리즘이 진단 툴에 통합되어 복잡한 데이터세트를 분석하고, 패혈증의 예후를 보다 정확하게 예측할 수 있게 되었습니다. 아울러, 프로칼시토닌(PCT), C-반응성 단백질(CRP), 젖산 수치 등의 바이오마커 기반 검사의 보급으로 임상의는 패혈증의 중증도 및 진행 상황에 관한 중요한 정보를 얻을 수 있게 되었으며, 이는 첨단 진단 시장의 확장을 주도하고 있습니다.

패혈증 진단 도입을 주도하고 있는 시장 부문은 어디인가?

패혈증 진단 시장은 기술, 제품 유형, 병원체, 검사 유형, 최종사용자 및 지역별로 세분화되어 있습니다. 주요 기술로는 분자 진단, 면역 분석법, 미생물학, 유세포분석법이 포함되며, 신속하고 정확한 병원체 동정 능력을 갖춘 분자 진단이 주도적인 위치를 차지하고 있습니다. 제품 유형은 장비와 시약부터 소프트웨어 및 서비스에 이르기까지 다양하지만, 지속적인 수요가 있으며, 시약 및 소모품이 가장 큰 점유율을 차지하고 있습니다. 패혈증 진단의 대상이 되는 병원체에는 세균, 진균, 바이러스가 포함되지만, 임상 현장에서 세균성 감염증의 발생률이 높기 때문에 세균성 패혈증 진단이 가장 일반적입니다. 패혈증 진단의 최종사용자로는 병원, 병리 검사실, 연구 기관 등이 포함되지만, 중환자실(ICU) 및 응급실의 패혈증 사례 수가 많기 때문에 병원이 시장을 독점하고 있습니다. 지역별로는 첨단인 의료 인프라와 높은 인지도 덕분에 북미와 유럽이 주요 시장을 형성하고 있으나, 아시아태평양은 의료 투자 증가와 패혈증에 대한 의식의 향상에 힘입어 고성장 지역으로 부상하고 있습니다.

패혈증 진단 시장의 성장을 촉진하는 주요 시장 촉진요인은 무엇인가?

패혈증 진단 시장의 성장은 패혈증 유병률 증가, 신속하고 정확한 진단 툴의 필요성, 분자 진단 및 바이오마커 기반 진단 기술의 발전 등 여러 요인에 의해 주도되고 있습니다. 신속한 결과 제공과 높은 민감도를 실현하는 현장 진단(POC) 기기 및 자동화 플랫폼의 개발이 병원 및 진단 검사실에서의 시장 도입을 촉진하고 있습니다. 맞춤형 의료와 표적 치료에 대한 관심이 높아짐에 따라 병원체를 정확하게 동정하고 항생제 감수성 검사를 가능하게 하는 첨단 패혈증 진단 기술의 활용이 확대되고 있습니다. 패혈증 사망률 감소와 조기 발견 향상을 목표로 하는 정부 주도의 노력과 의료 프로그램의 증가는 시장 성장을 위한 새로운 기회를 창출하고 있습니다. 또한 새로운 패혈증 바이오마커, AI를 활용한 진단 툴, 신속한 다중 검사법에 대한 연구개발 투자의 증가도 시장 확대를 지원하고 있습니다.

부문:

제품·서비스(기기, 혈액 배양 배지, 어세이 키트 및 시약, 소프트웨어), 기술(미생물학 기술, 분자진단 기술, 면역측정 기술, 유세포분석 기술, 기타 기술), 병원체(세균성 패혈증 병원체, 진균성 패혈증 병원체, 바이러스성 패혈증 병원체, 기타 병원체), 검사( 임상 검사, PoC 검사), 최종 용도(병원·진료소, 병리·검사 기관 , 기타)

주요 기업

  • Abbott Diagnostics
  • Axis-Shield Diagnostics Ltd
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Bruker Corporation
  • Cytosorbents Corporation
  • Danaher Corporation
  • EKF Diagnostics Holdings PLC
  • Immunexpress Inc.
  • Luminex Corporation
  • Mitsubishi Chemical Europe
  • Response Biomedical Corp.
  • Roche Diagnostics(Schweiz) AG
  • T2 Biosystems
  • Thermo Fisher Scientific, Inc.

해당 분야의 전문가 관점을 바탕으로 합니다.. 산업계, 기업, 학계에 걸친 분야 전문가들의 관점을 반영하여, 기존에 발표된 조사 결과 이상의 맥락을 더하고 있습니다.

시장의 초기 신호를 포착합니다. - 기존의 2차 조사에 완전히 반영되기 전에, 전문가 간의 대화, 기업의 동향, 시장과 관련된 논의를 통해 드러나는 변화를 추적합니다.

광범위하고 검증된 정보 기반을 활용합니다. - 컨퍼런스 세션, 기조 연설, 패널 토론, 블로그, 기업의 공시 정보, 연차 보고서, 기관 간행물 및 기타 검증된 정보 출처에서 얻은 인사이트를 통합합니다.

신호와 전략적 시장 방향성을 연결합니다. - 이러한 관점을 통합하여 시장이 어디로 향하고 있는지, 그 움직임을 주도하는 요인은 무엇인지, 그리고 전략에 있으며, 가장 중요할 가능성이 있는 동향은 무엇인지 파악합니다.

상세한 기업 정보를 제공합니다. - 시장 수준의 분석에 그치지 않고, 경쟁 환경에 참여하며 그 형성에 기여하고 있는 기업을 상세히 검증합니다.

주요 지역의 시장 점유율을 면밀히 검토합니다. - 단일 글로벌 시장 점유율 수치만으로는 전체적인 상황을 파악하기 어렵습니다. 경쟁 구조는 지역에 따라 크게 다를 수 있습니다. 분석상 관련성이 있는 경우, Market Glass의 보고서는 각 시장의 구조와 동향에 맞춰 상세도를 조정하여 주요 지역의 시장 점유율 분석을 심층적으로 다룹니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 26.10.27

Global Sepsis Diagnostics Market to Reach US$1.9 Billion by 2032

The global market for Sepsis Diagnostics estimated at US$1.2 Billion in the year 2025, is expected to reach US$1.9 Billion by 2032, growing at a CAGR of 7.2% over the analysis period 2025-2032. Instruments Offering, one of the segments analyzed in the report, is expected to record a 9.1% CAGR and reach US$762.2 Million by the end of the analysis period. Growth in the Blood Culture Media Offering segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$319.0 Million While China is Forecast to Grow at 11.4% CAGR

The Sepsis Diagnostics market in the U.S. is estimated at US$319.0 Million in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$439.6 Million by the year 2032 trailing a CAGR of 11.4% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 7.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Sepsis Diagnostics Market - Key Trends and Drivers Summarized

Why Is the Demand for Advanced Sepsis Diagnostics Growing Rapidly?

Sepsis, a life-threatening condition resulting from the body’s extreme response to infection, remains a leading cause of mortality worldwide. The demand for advanced sepsis diagnostics is rapidly increasing due to the need for early detection and timely intervention, which are critical for improving patient outcomes and reducing healthcare costs. Traditional diagnostic methods often face challenges related to time delays, accuracy, and the complexity of identifying sepsis at an early stage. In response, hospitals and clinical laboratories are increasingly adopting innovative diagnostic solutions, such as molecular diagnostics, rapid antigen tests, and biomarker-based assays, to enable precise and swift diagnosis of sepsis. The high prevalence of sepsis, particularly in intensive care units (ICUs) and emergency departments, is further driving the adoption of these advanced diagnostic tools globally.

How Are Technological Advancements Impacting Sepsis Diagnostics?

Technological advancements are significantly enhancing the sepsis diagnostics landscape, offering greater accuracy, speed, and reliability. Innovations in molecular diagnostics, including polymerase chain reaction (PCR) and next-generation sequencing (NGS), are enabling rapid identification of pathogens and their antibiotic resistance profiles, facilitating targeted therapy. Additionally, the development of automated platforms and point-of-care (POC) devices is bringing diagnostic capabilities closer to the bedside, reducing the time-to-results and improving clinical decision-making. AI and machine learning algorithms are also being integrated into diagnostic tools to analyze complex datasets and predict sepsis outcomes more accurately. Furthermore, the rise of biomarker-based tests, such as procalcitonin (PCT), C-reactive protein (CRP), and lactate levels, is providing clinicians with critical information on the severity and progression of sepsis, driving the market for advanced diagnostics.

Which Market Segments Are Leading the Adoption of Sepsis Diagnostics?

The sepsis diagnostics market is segmented by technology, product type, pathogen, testing type, end-user, and region. Key technologies include molecular diagnostics, immunoassays, microbiology, and flow cytometry, with molecular diagnostics leading due to their rapid and precise pathogen identification capabilities. Product types range from instruments and reagents to software and services, with reagents and consumables accounting for the largest share owing to their recurring demand. Pathogens covered in sepsis diagnostics include bacterial, fungal, and viral pathogens, with bacterial sepsis diagnostics being the most common due to the high incidence of bacterial infections in clinical settings. End-users of sepsis diagnostics include hospitals, pathology labs, and research institutes, with hospitals dominating the market due to the high volume of sepsis cases in ICUs and emergency departments. Geographically, North America and Europe are the leading markets due to advanced healthcare infrastructure and high awareness, while Asia-Pacific is emerging as a high-growth region driven by increasing healthcare investments and rising sepsis awareness.

What Are the Key Drivers of Growth in the Sepsis Diagnostics Market?

The growth in the sepsis diagnostics market is driven by several factors, including the increasing prevalence of sepsis, the need for rapid and accurate diagnostic tools, and advancements in molecular and biomarker-based diagnostics. The development of point-of-care devices and automated platforms that provide quick turnaround times and high sensitivity is driving market adoption across hospitals and diagnostic labs. The growing focus on personalized medicine and targeted therapies is expanding the use of advanced sepsis diagnostics that enable precise pathogen identification and antibiotic susceptibility testing. The rise of government initiatives and healthcare programs aimed at reducing sepsis mortality rates and improving early detection is creating new opportunities for market growth. Additionally, the increasing investments in R&D for novel sepsis biomarkers, AI-based diagnostic tools, and rapid multiplex assays are further supporting market expansion.

SCOPE OF STUDY:

The report analyzes the Sepsis Diagnostics market by the following Segments, and Geographic Regions/Countries:

Segments:

Offering (Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering, Software Offering); Technology (Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology, Other Technologies); Pathogen (Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen, Other Pathogens); Testing (Laboratory Testing, PoC Testing); End-Use (Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

  • Abbott Diagnostics
  • Axis-Shield Diagnostics Ltd
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Bruker Corporation
  • Cytosorbents Corporation
  • Danaher Corporation
  • EKF Diagnostics Holdings PLC
  • Immunexpress Inc.
  • Luminex Corporation
  • Mitsubishi Chemical Europe
  • Response Biomedical Corp.
  • Roche Diagnostics (Schweiz) AG
  • T2 Biosystems
  • Thermo Fisher Scientific, Inc.

WHAT SETS THIS REPORT APART FROM OTHERS?

Grounded in Domain Expert Perspectives - Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.

Captures Early Market Signals - Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.

Draws From a Broad, Validated Intelligence Base - Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.

Connects Signals With Strategic Market Direction - Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.

Provides In-Depth Company Intelligence - Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.

Market Share Is Examined Where It Matters - A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, Market Glass reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Global Economic Update
    • Sepsis Diagnostics - Global Key Competitors Percentage Market Share in 2026 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 46 Players Worldwide in 2026 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Sepsis Cases Globally Spurs Demand for Advanced Diagnostic Solutions
    • Technological Advancements in Molecular Diagnostics Propel Innovation in Sepsis Testing
    • Increasing Focus on Early Detection and Rapid Diagnosis Expands Addressable Market Opportunity
    • Growth of Point-of-Care Testing (POCT) for Sepsis Strengthens Business Case for Diagnostic Tools
    • Focus on Enhancing Sensitivity and Specificity of Sepsis Diagnostic Tests Drives Adoption
    • Emergence of Automated and AI-Driven Diagnostic Systems Generates New Market Opportunities
    • Rising Use of Biomarker-Based Diagnostics in Sepsis Detection Boosts Market Potential
    • Shift Towards Personalized Medicine and Targeted Therapies Expands Market Reach
    • Growing Emphasis on Sepsis Management in Critical Care Units Spurs Market Innovation
    • Emergence of Sepsis Diagnostics as a Key Component in Antimicrobial Stewardship Programs Expands Adoption
    • Expansion of Diagnostic Applications in Low- and Middle-Income Countries Creates New Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 2: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 3: World 13-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 4: World Sepsis Diagnostics Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032
    • TABLE 5: World Recent Past, Current & Future Analysis for Sepsis Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 6: World Historic Review for Sepsis Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 7: World 13-Year Perspective for Sepsis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
    • TABLE 8: World Recent Past, Current & Future Analysis for Instruments Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 9: World Historic Review for Instruments Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 10: World 13-Year Perspective for Instruments Offering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 11: World Recent Past, Current & Future Analysis for Blood Culture Media Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 12: World Historic Review for Blood Culture Media Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 13: World 13-Year Perspective for Blood Culture Media Offering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 14: World Recent Past, Current & Future Analysis for Assay Kits & Reagents Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 15: World Historic Review for Assay Kits & Reagents Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 16: World 13-Year Perspective for Assay Kits & Reagents Offering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 17: World Recent Past, Current & Future Analysis for Software Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 18: World Historic Review for Software Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 19: World 13-Year Perspective for Software Offering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 20: World Recent Past, Current & Future Analysis for Microbiology Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 21: World Historic Review for Microbiology Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 22: World 13-Year Perspective for Microbiology Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 23: World Recent Past, Current & Future Analysis for Molecular Diagnostics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 24: World Historic Review for Molecular Diagnostics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 25: World 13-Year Perspective for Molecular Diagnostics Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 26: World Recent Past, Current & Future Analysis for Immunoassays Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 27: World Historic Review for Immunoassays Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 28: World 13-Year Perspective for Immunoassays Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 29: World Recent Past, Current & Future Analysis for Flow Cytometry Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 30: World Historic Review for Flow Cytometry Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 31: World 13-Year Perspective for Flow Cytometry Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 32: World Recent Past, Current & Future Analysis for Bacterial Sepsis Pathogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 33: World Historic Review for Bacterial Sepsis Pathogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 34: World 13-Year Perspective for Bacterial Sepsis Pathogen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 35: World Recent Past, Current & Future Analysis for Fungal Sepsis Pathogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 36: World Historic Review for Fungal Sepsis Pathogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 37: World 13-Year Perspective for Fungal Sepsis Pathogen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 38: World Recent Past, Current & Future Analysis for Viral Sepsis Pathogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 39: World Historic Review for Viral Sepsis Pathogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 40: World 13-Year Perspective for Viral Sepsis Pathogen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 41: World Recent Past, Current & Future Analysis for Other Pathogens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 42: World Historic Review for Other Pathogens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 43: World 13-Year Perspective for Other Pathogens by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 44: World Recent Past, Current & Future Analysis for Laboratory Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 45: World Historic Review for Laboratory Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 46: World 13-Year Perspective for Laboratory Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 47: World Recent Past, Current & Future Analysis for PoC Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 48: World Historic Review for PoC Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 49: World 13-Year Perspective for PoC Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 50: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 51: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 52: World 13-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 53: World Recent Past, Current & Future Analysis for Pathology & Reference Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 54: World Historic Review for Pathology & Reference Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 55: World 13-Year Perspective for Pathology & Reference Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 56: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 57: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 58: World 13-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032

III. MARKET ANALYSIS

  • UNITED STATES
    • Sepsis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
    • TABLE 59: USA Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 60: USA Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 61: USA 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 62: USA Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 63: USA Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 64: USA 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 65: USA Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 66: USA Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 67: USA 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 68: USA Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 69: USA Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 70: USA 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 71: USA Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 72: USA Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 73: USA 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • CANADA
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 75: Canada Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 76: Canada 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 77: Canada Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 78: Canada Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 79: Canada 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 80: Canada Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 81: Canada Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 82: Canada 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 83: Canada Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 84: Canada Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 85: Canada 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 86: Canada Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 87: Canada Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 88: Canada 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • JAPAN
    • Sepsis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
    • TABLE 89: Japan Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 90: Japan Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 91: Japan 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 92: Japan Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 93: Japan Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 94: Japan 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 95: Japan Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 96: Japan Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 97: Japan 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 98: Japan Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 99: Japan Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 100: Japan 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 101: Japan Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 102: Japan Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 103: Japan 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • CHINA
    • Sepsis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
    • TABLE 104: China Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 105: China Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 106: China 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 107: China Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 108: China Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 109: China 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 110: China Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 111: China Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 112: China 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 113: China Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 114: China Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 115: China 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 116: China Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 117: China Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 118: China 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • EUROPE
    • Sepsis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
    • TABLE 119: Europe Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 120: Europe Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 121: Europe 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 122: Europe Recent Past, Current & Future Analysis for Sepsis Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 123: Europe Historic Review for Sepsis Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 124: Europe 13-Year Perspective for Sepsis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
    • TABLE 125: Europe Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 126: Europe Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 127: Europe 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 128: Europe Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 129: Europe Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 130: Europe 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 131: Europe Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 132: Europe Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 133: Europe 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 134: Europe Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 135: Europe Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 136: Europe 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • FRANCE
    • Sepsis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
    • TABLE 137: France Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 138: France Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 139: France 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 140: France Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 141: France Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 142: France 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 143: France Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 144: France Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 145: France 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 146: France Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 147: France Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 148: France 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 149: France Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 150: France Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 151: France 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • GERMANY
    • Sepsis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
    • TABLE 152: Germany Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 153: Germany Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 154: Germany 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 155: Germany Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 156: Germany Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 157: Germany 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 158: Germany Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 159: Germany Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 160: Germany 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 161: Germany Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 162: Germany Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 163: Germany 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 164: Germany Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 165: Germany Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 166: Germany 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • ITALY
    • TABLE 167: Italy Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 168: Italy Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 169: Italy 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 170: Italy Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 171: Italy Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 172: Italy 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 173: Italy Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 174: Italy Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 175: Italy 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 176: Italy Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 177: Italy Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 178: Italy 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 179: Italy Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 180: Italy Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 181: Italy 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • UNITED KINGDOM
    • Sepsis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
    • TABLE 182: UK Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 183: UK Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 184: UK 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 185: UK Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 186: UK Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 187: UK 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 188: UK Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 189: UK Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 190: UK 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 191: UK Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 192: UK Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 193: UK 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 194: UK Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 195: UK Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 196: UK 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • SPAIN
    • TABLE 197: Spain Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 198: Spain Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 199: Spain 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 200: Spain Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 201: Spain Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 202: Spain 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 203: Spain Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 204: Spain Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 205: Spain 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 206: Spain Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 207: Spain Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 208: Spain 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 209: Spain Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 210: Spain Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 211: Spain 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • RUSSIA
    • TABLE 212: Russia Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 213: Russia Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 214: Russia 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 215: Russia Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 216: Russia Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 217: Russia 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 218: Russia Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 219: Russia Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 220: Russia 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 221: Russia Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 222: Russia Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 223: Russia 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 224: Russia Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 225: Russia Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 226: Russia 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • REST OF EUROPE
    • TABLE 227: Rest of Europe Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 228: Rest of Europe Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 229: Rest of Europe 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 230: Rest of Europe Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 231: Rest of Europe Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 232: Rest of Europe 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 233: Rest of Europe Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 234: Rest of Europe Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 235: Rest of Europe 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 236: Rest of Europe Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 237: Rest of Europe Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 238: Rest of Europe 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 239: Rest of Europe Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 240: Rest of Europe Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 241: Rest of Europe 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • ASIA-PACIFIC
    • Sepsis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
    • TABLE 242: Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 243: Asia-Pacific Historic Review for Sepsis Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 244: Asia-Pacific 13-Year Perspective for Sepsis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
    • TABLE 245: Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 246: Asia-Pacific Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 247: Asia-Pacific 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 248: Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 249: Asia-Pacific Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 250: Asia-Pacific 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 251: Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 252: Asia-Pacific Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 253: Asia-Pacific 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 254: Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 255: Asia-Pacific Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 256: Asia-Pacific 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 257: Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 258: Asia-Pacific Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 259: Asia-Pacific 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • AUSTRALIA
    • Sepsis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
    • TABLE 260: Australia Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 261: Australia Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 262: Australia 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 263: Australia Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 264: Australia Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 265: Australia 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 266: Australia Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 267: Australia Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 268: Australia 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 269: Australia Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 270: Australia Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 271: Australia 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 272: Australia Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 273: Australia Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 274: Australia 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • INDIA
    • Sepsis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
    • TABLE 275: India Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 276: India Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 277: India 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 278: India Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 279: India Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 280: India 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 281: India Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 282: India Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 283: India 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 284: India Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 285: India Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 286: India 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 287: India Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 288: India Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 289: India 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • SOUTH KOREA
    • TABLE 290: South Korea Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 291: South Korea Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 292: South Korea 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 293: South Korea Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 294: South Korea Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 295: South Korea 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 296: South Korea Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 297: South Korea Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 298: South Korea 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 299: South Korea Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 300: South Korea Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 301: South Korea 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 302: South Korea Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 303: South Korea Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 304: South Korea 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • REST OF ASIA-PACIFIC
    • TABLE 305: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 306: Rest of Asia-Pacific Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 307: Rest of Asia-Pacific 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 308: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 309: Rest of Asia-Pacific Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 310: Rest of Asia-Pacific 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 311: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 312: Rest of Asia-Pacific Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 313: Rest of Asia-Pacific 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 314: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 315: Rest of Asia-Pacific Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 316: Rest of Asia-Pacific 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 317: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 318: Rest of Asia-Pacific Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 319: Rest of Asia-Pacific 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • LATIN AMERICA
    • Sepsis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
    • TABLE 320: Latin America Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 321: Latin America Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 322: Latin America 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 323: Latin America Recent Past, Current & Future Analysis for Sepsis Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 324: Latin America Historic Review for Sepsis Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 325: Latin America 13-Year Perspective for Sepsis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020, 2026 & 2032
    • TABLE 326: Latin America Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 327: Latin America Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 328: Latin America 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 329: Latin America Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 330: Latin America Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 331: Latin America 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 332: Latin America Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 333: Latin America Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 334: Latin America 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 335: Latin America Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 336: Latin America Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 337: Latin America 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • ARGENTINA
    • TABLE 338: Argentina Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 339: Argentina Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 340: Argentina 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 341: Argentina Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 342: Argentina Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 343: Argentina 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 344: Argentina Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 345: Argentina Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 346: Argentina 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 347: Argentina Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 348: Argentina Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 349: Argentina 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 350: Argentina Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 351: Argentina Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 352: Argentina 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • BRAZIL
    • TABLE 353: Brazil Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 354: Brazil Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 355: Brazil 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 356: Brazil Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 357: Brazil Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 358: Brazil 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 359: Brazil Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 360: Brazil Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 361: Brazil 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 362: Brazil Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 363: Brazil Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 364: Brazil 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 365: Brazil Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 366: Brazil Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 367: Brazil 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • MEXICO
    • TABLE 368: Mexico Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 369: Mexico Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 370: Mexico 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 371: Mexico Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 372: Mexico Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 373: Mexico 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 374: Mexico Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 375: Mexico Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 376: Mexico 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 377: Mexico Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 378: Mexico Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 379: Mexico 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 380: Mexico Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 381: Mexico Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 382: Mexico 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • REST OF LATIN AMERICA
    • TABLE 383: Rest of Latin America Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 384: Rest of Latin America Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 385: Rest of Latin America 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 386: Rest of Latin America Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 387: Rest of Latin America Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 388: Rest of Latin America 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 389: Rest of Latin America Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 390: Rest of Latin America Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 391: Rest of Latin America 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 392: Rest of Latin America Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 393: Rest of Latin America Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 394: Rest of Latin America 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 395: Rest of Latin America Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 396: Rest of Latin America Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 397: Rest of Latin America 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • MIDDLE EAST
    • Sepsis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
    • TABLE 398: Middle East Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 399: Middle East Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 400: Middle East 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 401: Middle East Recent Past, Current & Future Analysis for Sepsis Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 402: Middle East Historic Review for Sepsis Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 403: Middle East 13-Year Perspective for Sepsis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020, 2026 & 2032
    • TABLE 404: Middle East Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 405: Middle East Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 406: Middle East 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 407: Middle East Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 408: Middle East Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 409: Middle East 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 410: Middle East Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 411: Middle East Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 412: Middle East 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 413: Middle East Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 414: Middle East Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 415: Middle East 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • IRAN
    • TABLE 416: Iran Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 417: Iran Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 418: Iran 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 419: Iran Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 420: Iran Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 421: Iran 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 422: Iran Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 423: Iran Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 424: Iran 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 425: Iran Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 426: Iran Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 427: Iran 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 428: Iran Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 429: Iran Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 430: Iran 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • ISRAEL
    • TABLE 431: Israel Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 432: Israel Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 433: Israel 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 434: Israel Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 435: Israel Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 436: Israel 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 437: Israel Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 438: Israel Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 439: Israel 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 440: Israel Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 441: Israel Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 442: Israel 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 443: Israel Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 444: Israel Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 445: Israel 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • SAUDI ARABIA
    • TABLE 446: Saudi Arabia Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 447: Saudi Arabia Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 448: Saudi Arabia 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 449: Saudi Arabia Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 450: Saudi Arabia Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 451: Saudi Arabia 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 452: Saudi Arabia Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 453: Saudi Arabia Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 454: Saudi Arabia 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 455: Saudi Arabia Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 456: Saudi Arabia Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 457: Saudi Arabia 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 458: Saudi Arabia Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 459: Saudi Arabia Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 460: Saudi Arabia 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • UNITED ARAB EMIRATES
    • TABLE 461: UAE Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 462: UAE Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 463: UAE 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 464: UAE Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 465: UAE Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 466: UAE 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 467: UAE Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 468: UAE Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 469: UAE 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 470: UAE Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 471: UAE Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 472: UAE 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 473: UAE Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 474: UAE Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 475: UAE 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • REST OF MIDDLE EAST
    • TABLE 476: Rest of Middle East Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 477: Rest of Middle East Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 478: Rest of Middle East 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 479: Rest of Middle East Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 480: Rest of Middle East Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 481: Rest of Middle East 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 482: Rest of Middle East Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 483: Rest of Middle East Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 484: Rest of Middle East 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 485: Rest of Middle East Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 486: Rest of Middle East Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 487: Rest of Middle East 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 488: Rest of Middle East Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 489: Rest of Middle East Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 490: Rest of Middle East 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • AFRICA
    • Sepsis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
    • TABLE 491: Africa Recent Past, Current & Future Analysis for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 492: Africa Historic Review for Sepsis Diagnostics by Technology - Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 493: Africa 13-Year Perspective for Sepsis Diagnostics by Technology - Percentage Breakdown of Value Sales for Microbiology Technology, Molecular Diagnostics Technology, Immunoassays Technology, Flow Cytometry Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 494: Africa Recent Past, Current & Future Analysis for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 495: Africa Historic Review for Sepsis Diagnostics by Offering - Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 496: Africa 13-Year Perspective for Sepsis Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Blood Culture Media Offering, Assay Kits & Reagents Offering and Software Offering for the Years 2020, 2026 & 2032
    • TABLE 497: Africa Recent Past, Current & Future Analysis for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 498: Africa Historic Review for Sepsis Diagnostics by Pathogen - Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 499: Africa 13-Year Perspective for Sepsis Diagnostics by Pathogen - Percentage Breakdown of Value Sales for Bacterial Sepsis Pathogen, Fungal Sepsis Pathogen, Viral Sepsis Pathogen and Other Pathogens for the Years 2020, 2026 & 2032
    • TABLE 500: Africa Recent Past, Current & Future Analysis for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 501: Africa Historic Review for Sepsis Diagnostics by Testing - Laboratory Testing and PoC Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 502: Africa 13-Year Perspective for Sepsis Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and PoC Testing for the Years 2020, 2026 & 2032
    • TABLE 503: Africa Recent Past, Current & Future Analysis for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 504: Africa Historic Review for Sepsis Diagnostics by End-Use - Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 505: Africa 13-Year Perspective for Sepsis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pathology & Reference Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032

IV. COMPETITION

×

원하시는 정보를 찾아 드릴까요?

보안문자 새로고침
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기